Abstract
Early-onset Alzheimer’s disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with 18 F-flortaucipir and its relationship with clinical variables in amyloid PET–positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n = 390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n = 211). Participants with EOAD showed higher baseline tau PET burden, broader neuroanatomical involvement, and stronger associations of tau PET with amyloid PET and global cognition. Higher baseline tau PET burden in EOAD was independently validated in participants with EOAD from ADNI. Longitudinally, tau PET increased more rapidly in EOAD than in LOAD, independent of amyloid PET and clinical stage. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline.
Funding Information
  • National Institutes of Health (R01-NS139383)
  • National Institute on Aging (U19AG024904)
  • National Institute on Aging (R56-AG057195)
  • National Institute on Aging (P30-AG062422)
  • National Institute on Aging (R35-AG072362)
  • National Institute on Aging (U01-AG082350)
  • National Institute on Aging (R56-AG075744)
  • National Institute on Aging (U19-AG024904)
  • Alzheimer's Association (AARG-22-926940)
  • Alzheimer's Association (LDRFP-21-818464)
  • Alzheimer's Association (LEADS GENETICS-19-639372)
  • Alzheimer's Association (ZEN-21-848216)
  • American College of Radiology
  • Rainwater Charitable Foundation
  • Alliance for Therapies in Neuroscience

This publication has 54 references indexed in Scilit: